Mining the extracellular matrix for tissue engineering applications

Regenerative Medicine

Volumn 5, Issue 6, 2010, Pages 961-970

  Pradhan, Swati ^a   Farach Carson, Mary C ^a  

^a UNIVERSITY OF DELAWARE   (United States)

Author keywords

basement membrane protein; biomaterial; biomimetic scaffold; extracellular matrix derived peptide; tissue reconstruction

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; ASPARTYLGLYCYLGLUTAMYLALANINE; BIOMATERIAL; GLYCOCONJUGATE; GLYCYLPHENYLALANYLGLUTAMINYLGLYCYLGLUTAMYLARGININE; HEXAPEPTIDE; HYALURONIC ACID; ISOLEUCYLLYSYLVALYLALANYLVALINE; PENTAPEPTIDE; PERLECAN; TETRAPEPTIDE; TYROSYLISOLEUCYLGLYCYLSERYLARGININE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BASEMENT MEMBRANE; BINDING SITE; BIOCOMPATIBILITY; BIODEGRADABILITY; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL INTERACTION; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CELL SURVIVAL; CELL TYPE; ENDOTHELIUM CELL; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; INTRACELLULAR SIGNALING; MESENCHYMAL STEM CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; REGENERATIVE MEDICINE; REVIEW; TISSUE ENGINEERING; TISSUE REGENERATION;

ANIMALS; BASEMENT MEMBRANE; ENDOTHELIUM; EPITHELIUM; EXTRACELLULAR MATRIX; HUMANS; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 78649382350     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/rme.10.61     Document Type: Review

References (137)

1. Danen EH, Sonnenberg A: Integrins in regulation of tissue development and function. J. Pathol. 200(4), 471-480 (2003).
2. Rosso F, Giordano A, Barbarisi M, Barbarisi A: From cell-ECM interactions to tissue engineering. J. Cell Physiol. 199(2), 174-180 (2004).
3. Alberts B: Molecular Biology of the Cell (4th Edition). Garland Science, NY, USA (2002).
4. Labat-Robert J, Bihari-Varga M, Robert L: Extracellular matrix. FEBS Lett. 268(2), 386-393 (1990).
5. Weber KT, Sun Y, Katwa LC: Local regulation of extracellular matrix structure. Herz. 20(2), 81-88 (1995).
6. Schonherr E, Hausser HJ: Extracellular matrix and cytokines: a functional unit. Dev. Immunol. 7(2-4), 89-101 (2000).
7. Parameswaran K, Willems-Widyastuti A, Alagappan VK et al.: Role of extracellular matrix and its regulators in human airway smooth muscle biology. Cell Biochem. Biophys. 44(1), 139-146 (2006).
8. Pereira AL, Veras SS, Silveira EJ et al.: The role of matrix extracellular proteins and metalloproteinases in head and neck carcinomas: an updated review. Braz. J. Otorhinolaryngol. 71(1), 81-86 (2005).
9. Breitkreutz D, Mirancea N, Nischt R: Basement membranes in skin: unique matrix structures with diverse functions? Histochem. Cell Biol. 132(1), 1-10 (2009).
10. Erickson AC, Couchman JR: Still more complexity in mammalian basement membranes. J. Histochem. Cytochem. 48(10), 1291-1306 (2000).
11. Rowe RG, Weiss SJ: Breaching the basement membrane: who, when and how? Trends Cell Biol. 18(11), 560-574 (2008).
12. Bronzino JD: Tissue Engineering and Artifcial Organs. CRC/Taylor & Francis, FL, USA (2006).
13. Santoro MM, Gaudino G: Cellular and molecular facets of keratinocyte reepithelization during wound healing. Exp. Cell Res. 304(1), 274-286 (2005).
14. Timpl R, Brown JC: Supramolecular assembly of basement membranes. Bioessays 18(2), 123-132 (1996).
15. Miner JH, Yurchenco PD: Laminin functions in tissue morphogenesis. Annu. Rev. Cell Dev. Biol. 20, 255-284 (2004).
16. McKee KK, Harrison D, Capizzi S, Yurchenco PD: Role of laminin terminal globular domains in basement membrane assembly. J. Biol. Chem. 282(29), 21437-21447 (2007). (Pubitemid 47099937)
17. Aumailley M, Bruckner-Tuderman L, Carter WG et al.: A simplifed laminin nomenclature. Matrix Biol. 24(5), 326-332 (2005).
18. Macdonald PR, Lustig A, Steinmetz MO, Kammerer RA: Laminin chain assembly is regulated by specifc coiled-coil interactions. J. Struct. Biol. 170(2), 398-405 (2010).
19. McKee KK, Capizzi S, Yurchenco PD: Scaffold-forming and adhesive contributions of synthetic laminin-binding proteins to basement membrane assembly. J. Biol. Chem. 284(13), 8984-8994 (2009).
20. Durbeej M: Laminins. Cell Tissue Res. 339(1), 259-268 (2010).
21. Tzu J, Marinkovich MP: Bridging structure with function: structural, regulatory, and developmental role of laminins. Int. J. Biochem. Cell Biol. 40(2), 199-214 (2008).
22. Sugawara K, Tsuruta D, Ishii M, Jones JC, Kobayashi H: Laminin-332 and-511 in skin. Exp. Dermatol. 17(6), 473-480 (2008).
23. Li S, Liquari P, McKee KK et al.: Laminin-sulfatide binding initiates basement membrane assembly and enables receptor signaling in Schwann cells and fbroblasts. J. Cell Biol. 1(1), 179-189 (2005).
24. Sasaki T, Gohring W, Mann K et al.: Short arm region of laminin-5 g2 chain: structure, mechanism of processing and binding to heparin and proteins. J. Mol. Biol. 314(4), 751-763 (2001).
25. Gordon MK, Hahn RA: Collagens. Cell Tissue Res. 339(1), 247-257 (2010).
26. Shoulders MD, Raines RT: Collagen structure and stability. Annu. Rev. Biochem. 78, 929-958 (2009).
27. Khoshnoodi J, Pedchenko V, Hudson BG: Mammalian collagen IV. Microsc. Res. Tech. 71(5), 357-370 (2008).
28. Battaglia C, Mayer U, Aumailley M, Timpl R: Basement-membrane heparan sulfate proteoglycan binds to laminin by its heparan sulfate chains and to nidogen by sites in the protein core. Eur. J. Biochem. 208(2), 359-366 (1992).
29. Iozzo RV: Basement membrane proteoglycans: from cellar to ceiling. Nat. Rev. Mol. Cell Biol. 6(8), 646-656 (2005).
30. Yurchenco PD, Amenta PS, Patton BL: Basement membrane assembly, stability and activities observed through a developmental lens. Matrix Biol. 22(7), 521-538 (2004).
31. Hallmann R, Horn N, Selg M et al.: Expression and function of laminins in the embryonic and mature vasculature. Physiol. Rev. 85(3), 979-1000 (2005).
32. Davis GE, Senger DR: Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 97(11), 1093-1107 (2005).
33. Miner JH, Patton BL, Lentz SI et al.: The laminin a-chains: expression, developmental transitions, and chromosomal locations of a1-5, identifcation of heterotrimeric laminins 8-11, and cloning of a novel a3 isoform. J. Cell Biol. 137(3), 685-701 (1997).
34. Thyboll J, Kortesmaa J, Cao R et al.: Deletion of the laminin a4 chain leads to impaired microvessel maturation. Mol. Cell Biol. 22(4), 1194-1202 (2002).
35. Miner JH, Cunningham J, Sanes JR: Roles for laminin in embryogenesis: exencephaly, syndactyly, and placentopathy in mice lacking the laminin a5 chain. J. Cell Biol. 143(6), 1713-1723 (1998).
36. Cheng YS, Champliaud MF, Burgeson RE, Marinkovich MP, Yurchenco PD: Self-assembly of laminin isoforms. J. Biol. Chem. 272(50), 31525-31532 (1997).
37. Kalluri R: Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 3(6), 422-433 (2003).
38. Chen L, Miyamura N, Ninomiya Y, Handa JT: Distribution of the collagen IV isoforms in human Bruch's membrane. Br. J. Ophthalmol. 87(2), 212-215 (2003). (Pubitemid 36152750)
39. Poschl E, Schlotzer-Schrehardt U, Brachvogel B et al.: Collagen IV is essential for basement membrane stability but dispensable for initiation of its assembly during early development. Development 131(7), 1619-1628 (2004).
40. Costell M, Gustafsson E, Aszodi A et al.: Perlecan maintains the integrity of cartilage and some basement membranes. J. Cell Biol. 147(5), 1109-1122 (1999).
41. Bix G, Fu J, Gonzalez EM et al.: Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through a2b 1 integrin. J. Cell Biol. 166(1), 97-109 (2004).
42. Ruegg C, Hasmim M, Lejeune FJ, Alghisi GC: Antiangiogenic peptides and proteins: from experimental tools to clinical drugs. Biochim. Biophys. Acta 1765(2), 155-177 (2006).
43. Bix G, Iozzo RA, Woodall B et al.: Endorepellin, the C-terminal angiostatic module of perlecan, enhances collagen-platelet responses via the a2b 1-integrin receptor. Blood 109(9), 3745-3748 (2007).
44. Mongiat M, Sweeney SM, San Antonio JD, Fu J, Iozzo RV: Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J. Biol. Chem. 278(6), 4238-4249 (2003).
45. Bix G, Castello R, Burrows M et al.: Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J. Natl Cancer Inst. 98(22), 1634-1646 (2006).
46. O'Reilly MS, Holmgren L, Chen C, Folkman J: Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2(6), 689-692 (1996).
47. Rehn M, Pihlajaniemi T: a1(XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen. Proc. Natl Acad. Sci. USA 91(10), 4234-4238 (1994).
48. Ma DH, Chen JK, Zhang F et al.: Regulation of corneal angiogenesis in limbal stem cell defciency Prog. Retin. Eye Res. 25(6), 563-590 (2006).
49. Hamilton R, Campbell FR: Immunochemical localization of extracellular materials in bone marrow of rats. Anat. Rec. 231(2), 218-224 (1991).
50. Gordon MY: Extracellular matrix of the marrow microenvironment. Br. J. Haematol. 70(1), 1-4 (1988).
51. Djouad F, Bouff C, Ghannam S, Noel D, Jorgensen C: Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat. Rev. Rheumatol. 5(7), 392-399 (2009).
52. Roelen BA, Dijke P: Controlling mesenchymal stem cell differentiation by TGF-b family members. J. Orthop. Sci. 8(5), 740-748 (2003).
53. Kohane DS, Langer R: Polymeric biomaterials in tissue engineering. Pediatr. Res. 63(5), 487-491 (2008).
54. Baroli B: Hydrogels for tissue engineering and delivery of tissue-inducing substances. J. Pharm. Sci. 96(9), 2197-2223 (2007).
55. Kretlow JD, Klouda L, Mikos AG: Injectable matrices and scaffolds for drug delivery in tissue engineering. Adv. Drug Deliv. Rev. 59(4-5), 263-273 (2007).
56. Chung HJ, Park TG: Surface engineered and drug releasing pre-fabricated scaffolds for tissue engineering. Adv. Drug Deliv. Rev. 59(4-5), 249-262 (2007).
57. Kohane DS, Tse JY, Yeo Y et al.: Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum. J. Biomed. Mater. Res. A 77(2), 351-361 (2006).
58. Sisson K, Zhang C, Farach-Carson MC, Chase DB, Rabolt JF: Evaluation of cross-linking methods for electrospun gelatin on cell growth and viability Biomacromolecules (2009) (Epub ahead of print).
59. Ruoslahti E, Pierschbacher MD: New perspectives in cell adhesion: RGD and integrins. Science 238(4826), 491-497 (1987).
60. Yamada KM, Kennedy DW: Dualistic nature of adhesive protein function: fbronectin and its biologically active peptide fragments can autoinhibit fbronectin function. J. Cell Biol. 99(1 Pt 1), 29-36 (1984).
61. Gartner TK, Bennett JS: The tetrapeptide analogue of the cell attachment site of fbronectin inhibits platelet aggregation and fbrinogen binding to activated platelets. J. Biol. Chem. 260(22), 11891-11894 (1985).
62. Ginsberg M, Pierschbacher MD, Ruoslahti E, Marguerie G, Plow E: Inhibition of fbronectin binding to platelets by proteolytic fragments and synthetic peptides which support fbroblast adhesion. J. Biol. Chem. 260(7), 3931-3936 (1985).
63. Plow EF, Pierschbacher MD, Ruoslahti E, Marguerie GA, Ginsberg MH: The effect of Arg-Gly-Asp-containing peptides on fbrinogen and von Willebrand factor binding to platelets. Proc. Natl Acad. Sci. USA 82(23), 8057-8061 (1985).
64. Plow EF, McEver R P, Coller BS et al.: Related binding mechanisms for fbrinogen, fbronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 66(3), 724-727 (1985).
65. Hayman EG, Pierschbacher MD, Suzuki S, Ruoslahti E: Vitronectin-a major cell attachment-promoting protein in fetal bovine serum. Exp. Cell Res. 160(2), 245-258 (1985).
66. Gardner JM, Hynes RO: Interaction of fbronectin with its receptor on platelets. Cell 42(2), 439-448 (1985).
67. Barczyk M, Carracedo S, Gullberg D: Integrins. Cell Tissue Res. 339(1), 2-80 (2010).
68. Pytela R, Suzuki S, Breuss J, Erle DJ, Sheppard D: Polymerase chain reaction cloning with degenerate primers: homology-based identifcation of adhesion molecules. Methods Enzymol. 245, 420-451 (1994).
69. Pytela R, Pierschbacher MD, Ruoslahti E: A 125/115-kDa cell surface receptor specifc for vitronectin interacts with the arginine-glycine-aspartic acid adhesion sequence derived from fbronectin. Proc. Natl Acad. Sci. USA 82(17), 5766-5770 (1985).
70. Pytela R, Pierschbacher MD, Ruoslahti E: Identifcation and isolation of a 140 kd cell surface glycoprotein with properties expected of a fbronectin receptor. Cell 40(1), 191-198 (1985).
71. Ruoslahti E: RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697-715 (1996).
72. Bajt ML, Ginsberg MH, Frelinger AL 3rd, Berndt MC, Loftus JC: A spontaneous mutation of integrin aIIb b3 (platelet glycoprotein IIb-IIIa) helps defne a ligand binding site. J. Biol. Chem. 267(6), 3789-3794 (1992).
73. Bajt ML, Loftus JC: Mutation of a ligand binding domain of b3 integrin. Integral role of oxygenated residues in aIIb b3 (GPIIb-IIIa) receptor function. J. Biol. Chem. 2(33), 20913-20919 (1994).
74. Smith JW, Cheresh DA: The Arg-Gly-Asp binding domain of the vitronectin receptor. Photoaffnity cross-linking implicates amino acid residues 61-203 of the b subunit. J. Biol. Chem. 263(35), 18726-18731 (1988).
75. Davis GE, Bayless KJ, Davis MJ, Meininger GA: Regulation of tissue injury responses by the exposure of matricryptic sites within extracellular matrix molecules. Am. J. Pathol. 156(5), 1489-1498 (2000).
76. Huveneers S, Truong H, Fassler R, Sonnenberg A, Danen EH: Binding of soluble fbronectin to integrin a5b1-link to focal adhesion redistribution and contractile shape. J. Cell Sci. 121(Pt 15), 2452-2462 (2008).
77. Mintz KP, Grzesik WJ, Midura RJ et al.: Purifcation and fragmentation of nondenatured bone sialoprotein: evidence for a cryptic, RGD-resistant cell attachment domain. J. Bone Miner. Res. 8(8), 985-995 (1993).
78. Davis GE: Matricryptic sites control tissue injury responses in the cardiovascular system: relationships to pattern recognition receptor regulated events. J. Mol. Cell Cardiol. 48(3), 454-460 (2010).
79. Lotz MM, Burdsal CA, Erickson HP, McClay DR: Cell adhesion to fbronectin and tenascin: quantitative measurements of initial binding and subsequent strengthening response. J. Cell Biol. 109(4 Pt 1), 1795-1805 (1989).
80. Shin H, Temenoff JS, Bowden GC et al.: Osteogenic differentiation of rat bone marrow stromal cells cultured on Arg-Gly-Asp modifed hydrogels without dexamethasone and b-glycerol phosphate. Biomaterials 26(17), 3645-3654 (2005).
81. Shin H, Zygourakis K, Farach-Carson MC, Yaszemski MJ, Mikos AG: Modulation of differentiation and mineralization of marrow stromal cells cultured on biomimetic hydrogels modifed with Arg-Gly-Asp containing peptides. J. Biomed. Mater. Res. A (3), 535-543 (2004).
82. Shin H, Zygourakis K, Farach-Carson MC, Yaszemski MJ, Mikos AG: Attachment, proliferation, and migration of marrow stromal osteoblasts cultured on biomimetic hydrogels modifed with an osteopontin-derived peptide. Biomaterials 25(5), 895-906 (2004).
83. Iwamoto Y, Robey FA, Graf J et al.: YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science 238(4830), 1132-1134 (1987).
84. Bushkin-Harav I, Littauer UZ: Involvement of the YIGSR sequence of laminin in protein tyrosine phosphorylation. FEBS Lett. 424(3), 243-247 (1998).
85. Bilozur ME, Hay ED: Neural crest migration in 3D extracellular matrix utilizes laminin, fbronectin, or collagen. Dev. Biol. 125(1), 19-33 (1988).
86. Hubbell JA, Massia SP, Desai NP, Drumheller PD: Endothelial cell-selective materials for tissue engineering in the vascular graft via a new receptor. Biotechnology (NY) 9(6), 568-572 (1991).
87. Jun HW, West JL: Endothelialization of microporous YIGSR/PEG-modifed polyurethaneurea. Tissue Eng. 11(7-8), 1133-1140 (2005).
88. Graf J, Ogle RC, Robey FA et al.: A pentapeptide from the laminin B1 chain mediates cell adhesion and binds the 67,000 laminin receptor. Biochemistry 26(22), 6896-6900 (1987).
89. Castronovo V: Laminin receptors and laminin-binding proteins during tumor invasion and metastasis. Invasion Metastasis 13(1), 1-30 (1993).
90. Tashiro K, Sephel GC, Weeks B et al.: A synthetic peptide containing the IKVAV sequence from the A chain of laminin mediates cell attachment, migration, and neurite outgrowth. J. Biol. Chem. 264(27), 16174-16182 (1989).
91. Sephel GC, Tashiro K, Sasaki M et al.: A laminin-pepsin fragment with cell attachment and neurite outgrowth activity at distinct sites. Dev. Biol. 135(1), 172-181 (1989).
92. Sephel GC, Tashiro KI, Sasaki M et al.: Laminin A chain synthetic peptide which supports neurite outgrowth. Biochem. Biophys. Res. Commun. 162(2), 821-829 (1989).
93. Nomizu M, Weeks BS, Weston CA et al.: Structure-activity study of a laminin a-1 chain active peptide segment Ile-Lys-Val-Ala-Val (IKVAV). FEBS Lett. 365(2-3), 227-231 (1995).
94. Grant DS, Tashiro K, Segui-Real B et al.: Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58(5), 933-943 (1989).
95. Hopker VH, Shewan D, Tessier-Lavigne M, Poo M, Holt C: Growth-cone attraction to netrin-1 is converted to repulsion by laminin-1. Nature 401(6748), 69-73 (1999).
96. Ratcliffe EM, D'Autreaux F, Gershon MD: Laminin terminates the Netrin/DCC mediated attraction of vagal sensory axons. Dev. Neurobiol. 68(7), 960-971 (2008).
97. Reyes CD, Garcia AJ: Engineering integrin-specifc surfaces with a triple-helical collagen-mimetic peptide. J. Biomed. Mater. Res. A 65(4), 511-523 (2003).
98. Reyes CD, Garcia AJ: a2b1 integrin-specifc collagen-mimetic surfaces supporting osteoblastic differentiation. J. Biomed. Mater. Res. A (4), 591-600 (2004).
99. Wojtowicz AM, Shekaran A, Oest ME et al.: Coating of biomaterial scaffolds with the collagen-mimetic peptide GFOGER for bone defect repair. Biomaterials 31(9), 2574-2582 (2010).
100. Mizuno M, Fujisawa R, Kuboki Y: Type I collagen-induced osteoblastic differentiation of bone-marrow cells mediated by collagen-a2b1 integrin interaction. J. Cell Physiol. 184(2), 207-213 (2000).
101. Jikko A, Harris SE, Chen D, Mendrick DL, Damsky CH: Collagen integrin receptors regulate early osteoblast differentiation induced by BMP-2. J. Bone Miner. Res. 14(7), 1075-1083 (1999).
102. 2+]i signalling in human dermal fbroblasts. Biochim. Biophys. Acta 1746(1), 28-37 (2005).
103. Yamaguchi K, Ura H, Yasoshima T et al.: Establishment and characterization of a human gastric carcinoma cell line that is highly metastatic to lymph nodes. J. Exp. Clin. Cancer Res. 19(1), 113-120 (2000).
104. Mizuno M, Kuboki Y: Osteoblast-related gene expression of bone marrow cells during the osteoblastic differentiation induced by type I collagen. J. Biochem. 129(1), 133-138 (2001).
105. McCann TJ, Mason WT, Meikle MC, McDonald F: A collagen peptide motif activates tyrosine kinase-dependent calcium signalling pathways in human osteoblast-like cells. Matrix Biol. 16(5), 273-283 (1997).
106. Farach-Carson MC, Hecht JT, Carson DD: Heparan sulfate proteoglycans: key players in cartilage biology. Crit. Rev. Eukaryot. Gene Expr. 15(1), 29-48 (2005).
107. Schofeld KP, Gallagher JT, David G: Expression of proteoglycan core proteins in human bone marrow stroma. Biochem. J. 343 (Pt 3), 663-668 (1999).
108. Farach-Carson MC, Brown AJ, Lynam M, Safran JB, Carson DD: A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation. Matrix Biol. 27(2), 150-160 (2008).
109. Pradhan S, Zhang C, Jia X et al.: Perlecan domain IV peptide stimulates salivary gland cell assembly in vitro. Tissue Eng. Part A. 15(11), 3309-3320 (2009).
110. Hartman O, Zhang C, Adams EL et al.: Biofunctionalization of electrospun PCL-based scaffolds with perlecan domain IV peptide to create a 3-D pharmacokinetic cancer model. Biomaterials 31(21), 5700-5718 (2010).
111. Underhill C: CD44: the hyaluronan receptor. J. Cell Sci. 103(Pt 2), 293-298 (1992).
112. Yang B, Zhang L, Turley EA: Identifcation of two hyaluronan-binding domains in the hyaluronan receptor RHAMM. J. Biol. Chem. 268(12), 8617-8623 (1993).
113. Neame PJ, Barry FP: The link proteins. Experientia 49(5), 393-402 (1993).
114. Watanabe H, Cheung SC, Itano N, Kimata K, Yamada Y: Identifcation of hyaluronan-binding domains of aggrecan. J. Biol. Chem. 272(44), 28057-28065 (1997).
115. Zimmermann DR, Ruoslahti E: Multiple domains of the large fbroblast proteoglycan, versican. EMBO J. 8(10), 2975-2981 (1989).
116. Hofmann M, Fieber C, Assmann V et al.: Identifcation of IHABP, a 95 kDa intracellular hyaluronate binding protein. J. Cell Sci. 111(Pt 12), 1673-1684 (1998).
117. Acharya S, Rodriguez IR, Moreira EF et al.: SPACR, a novel interphotoreceptor matrix glycoprotein in human retina that interacts with hyaluronan. J. Biol. Chem. 273(47), 31599-31606 (1998).
118. Grammatikakis N, Grammatikakis A, Yoneda M et al.: A novel glycosaminoglycan-binding protein is the vertebrate homologue of the cell cycle control protein, Cdc37. J. Biol. Chem. 270(27), 16198-16205 (1995).
119. Das S, Deb TB, Kumar R, Datta K: Multifunctional activities of human fbroblast 34-kDa hyaluronic acid-binding protein. Gene 190(1), 223-225 (1997).
120. Acharya S, Foletta VC, Lee JW et al.: SPACRCAN, a novel human interphotoreceptor matrix hyaluronan-binding proteoglycan synthesized by photoreceptors and pinealocytes. J. Biol. Chem. 275(10), 45-55 (2000).
121. Amemiya K, Nakatani T, Saito A, Suzuki A, Munakata H: Hyaluronan-binding motif identifed by panning a random peptide display library. Biochim. Biophys. Acta 1724(1-2), 94-99 (2005).
122. Yang WD, Gomes RR Jr, Alicknavitch M, Farach-Carson MC, Carson DD: Perlecan domain I promotes fbroblast growth factor 2 delivery in collagen I fbril scaffolds. Tissue Eng. 11(1-2), 76-89 (2005).
123. Kirn-Safran CB, Gomes RR, Brown AJ, Carson DD: Heparan sulfate proteoglycans: coordinators of multiple signaling pathways during chondrogenesis. Birth Defects Res. C Embryo Today 72(1), 69-88 (2004).
124. Knox S, Merry C, Stringer S, Melrose J, Whitelock J: Not all perlecans are created equal: interactions with fbroblast growth factor (FGF) 2 and FGF receptors. J. Biol. Chem. 277(17), 14657-14665 (2002).
125. Jiang X, Couchman JR: Perlecan and tumor angiogenesis. J. Histochem. Cytochem. 51(11), 1393-1410 (2003).
126. Ruppert R, Hoffmann E, Sebald W: Human bone morphogenetic protein 2 contains a heparin-binding site which modifes its biological activity. Eur. J. Biochem. 237(1), 295-302 (1996).
127. Gomes RR Jr, Farach-Carson MC, Carson DD: Perlecan functions in chondrogenesis: insights from in vitro and in vivo models. Cells Tissues Organs 176(1-3), 79-86 (2004).
128. Gustafsson E, Aszodi A, Ortega N et al.: Role of collagen type II and perlecan in skeletal development. Ann. NY Acad. Sci. 995, 140-150 (2003).
129. Arikawa-Hirasawa E, Watanabe H, Takami H, Hassell JR, Yamada Y: Perlecan is essential for cartilage and cephalic development. Nat. Genet. 23(3), 354-358 (1999).
130. Yang W, Gomes RR, Brown AJ et al.: Chondrogenic differentiation on perlecan domain I, collagen II, and bone morphogenetic protein-2-based matrices. Tissue Eng. 12(7), 2009-2024 (2006).
131. Gotoh Y, Niimi S, Hayakawa T, Miyashita T: Preparation of lactose-silk fbroin conjugates and their application as a scaffold for hepatocyte attachment. Biomaterials 25(6), 1131-1140 (2004).
132. Gobin AS, West JL: Cell migration through defned, synthetic ECM analogs. FASEB J. 16(7), 751-753 (2002).
133. Lutolf MP, Hubbell JA: Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nat. Biotechnol. 23(1), 47-55 (2005).
134. Lutolf MP, Lauer-Fields JL, Schmoekel HG et al.: Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc. Natl Acad. Sci. USA 100(9), 5413-5418 (2003).
135. Fischbach C, Mooney DJ: Polymers for pro-and anti-angiogenic therapy. Biomaterials 28(12), 20-76 (2007).
136. Goldberg M, Langer R, Jia X: Nanostructured materials for applications in drug delivery and tissue engineering. J. Biomater. Sci. Polym. Ed. 18(3), 241-268 (2007).
137. Dunehoo AL, Anderson M, Majumdar S et al.: Cell adhesion molecules for targeted drug delivery J. Pharm. Sci. 95(9), 1856-1872 (2006).